Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C15H14N4O.H2O |
| Molecular Weight | 550.611 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC1=CC=NC2=C1NC(=O)C3=C(N=CC=C3)N2C4CC4.CC5=CC=NC6=C5NC(=O)C7=C(N=CC=C7)N6C8CC8
InChI
InChIKey=KMTLSXAXTLQBKJ-UHFFFAOYSA-N
InChI=1S/2C15H14N4O.H2O/c2*1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10;/h2*2-3,6-8,10H,4-5H2,1H3,(H,18,20);1H2
| Molecular Formula | C15H14N4O |
| Molecular Weight | 266.2979 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00238Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nevirapine.html
Sources: http://www.drugbank.ca/drugs/DB00238
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nevirapine.html
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time. Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. Nevirapine is used for use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL614530 |
239.0 µM [EC50] | ||
Target ID: CHEMBL378 |
0.31 nM [EC50] | ||
Target ID: CHEMBL247 Sources: http://www.drugbank.ca/drugs/DB00238 |
250.0 nM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Viramune Approved UseVIRAMUNE is an NNRTI indicated for combination antiretroviral treatment of HIV-1 infection Launch Date1995 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2060 ng/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
161000 ng × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
82000 ng × h/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
96700 ng × h/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
45 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
40% |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
200 mg single, oral Overdose |
unhealthy, 8-days-old Health Status: unhealthy Age Group: 8-days-old Sex: F Sources: |
Other AEs: Neutropenia, Hyperlactatemia... |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Disc. AE: Rash, Stevens-Johnson syndrome... AEs leading to discontinuation/dose reduction: Rash (2%) Sources: Stevens-Johnson syndrome (1%) Transaminases increased (1%) ALT increased (1%) GGT increased (<1%) AST increased (<1%) Hepatic enzyme increased (<1%) Hepatitis (1%) Hepatotoxicity (1%) Hepatitis acute (<1%) Hepatitis toxic (<1%) Nausea (1%) Malaise (1%) Pyrexia (1%) Fatigue (1%) Vascular disorders (<1%) |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Disc. AE: Rash, Drug rash with eosinophilia and systemic symptoms... AEs leading to discontinuation/dose reduction: Rash (2%) Sources: Drug rash with eosinophilia and systemic symptoms (<1%) Transaminases increased (1%) ALT increased (<1%) GGT increased (<1%) AST increased (<1%) Hepatic enzyme increased (<1%) Hepatitis (1%) Hepatotoxicity (<1%) Hepatitis acute (<1%) Hepatitis toxic (<1%) Nausea (<1%) Malaise (<1%) Pyrexia (<1%) Fatigue (<1%) Vascular disorders (<1%) Musculoskeletal and connective tissue disorders (<1%) |
800 mg 1 times / day multiple, oral Overdose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Disc. AE: Hepatotoxicity, Reaction skin... AEs leading to discontinuation/dose reduction: Hepatotoxicity (grade 5) Sources: Reaction skin (severe) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Hyperlactatemia | 200 mg single, oral Overdose |
unhealthy, 8-days-old Health Status: unhealthy Age Group: 8-days-old Sex: F Sources: |
|
| Neutropenia | mild | 200 mg single, oral Overdose |
unhealthy, 8-days-old Health Status: unhealthy Age Group: 8-days-old Sex: F Sources: |
| ALT increased | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Fatigue | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Hepatitis | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Hepatotoxicity | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Malaise | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Nausea | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Pyrexia | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Stevens-Johnson syndrome | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Transaminases increased | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Rash | 2% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| AST increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| GGT increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Hepatic enzyme increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Hepatitis acute | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Hepatitis toxic | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Vascular disorders | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Hepatitis | 1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Transaminases increased | 1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Rash | 2% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| ALT increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| AST increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Drug rash with eosinophilia and systemic symptoms | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Fatigue | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| GGT increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Hepatic enzyme increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Hepatitis acute | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Hepatitis toxic | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Hepatotoxicity | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Malaise | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Musculoskeletal and connective tissue disorders | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Nausea | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Pyrexia | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Vascular disorders | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
| Hepatotoxicity | grade 5 Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
| Reaction skin | severe Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. | 2001-09 |
|
| Antiviral drugs: current state of the art. | 2001-08 |
|
| Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. | 2001-07-06 |
|
| Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. | 2001-07-06 |
|
| The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. | 2001-07-01 |
|
| Sequence-specific detection of individual DNA strands using engineered nanopores. | 2001-07 |
|
| Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors. | 2001-07 |
|
| South Africa in crisis on HIV/AIDS treatment. | 2001-06-29 |
|
| Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. | 2001-06-15 |
|
| High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. | 2001-06-15 |
|
| Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). | 2001-06-15 |
|
| 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. | 2001-06-07 |
|
| The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. | 2001-06-01 |
|
| Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease. | 2001-06 |
|
| Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. | 2001-06 |
|
| Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine. | 2001-06 |
|
| New developments in anti-HIV chemotherapy. | 2001-05-12 |
|
| HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. | 2001-05-04 |
|
| An in vivo model for HIV resistance development. | 2001-05-01 |
|
| Jaundice and hepatocellular damage associated with nevirapine therapy. | 2001-05 |
|
| High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. | 2001-04-15 |
|
| Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine. | 2001-04-15 |
|
| Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting. | 2001-04-13 |
|
| Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. | 2001-04-13 |
|
| [Highly active antiretroviral therapy with nevirapine. Therapy compliance determines success]. | 2001-04-02 |
|
| [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor]. | 2001-04-02 |
|
| Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome. | 2001-04-01 |
|
| Rwanda to receive cheaper anti-HIV drugs for chronic treatment and free viramune to prevent viral transmission from mother to child. | 2001-04 |
|
| Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. | 2001-04 |
|
| Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription. | 2001-04 |
|
| [Cutaneous adverse events related to simultaneous nevirapine treatment and pneumococcal vaccination in HIV-infected patients]. | 2001-03-31 |
|
| Sequencing antiretroviral drugs. | 2001-03-30 |
|
| From the Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. | 2001-03-27 |
|
| Efficiency comparisons of rank and permutation tests based on summary statistics computed from repeated measures data. | 2001-03-15 |
|
| Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. | 2001-03-03 |
|
| International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. | 2001-03-01 |
|
| [Nevirapine and clinical withdrawal syndrome]. | 2001-03 |
|
| Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis. | 2001-03 |
|
| Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. | 2001-02-26 |
|
| Simple and rapid determination of nevirapine in human serum by reversed-phase high-performance liquid chromatography. | 2001-02-25 |
|
| Drug interaction between St John's wort and nevirapine. | 2001-02-16 |
|
| Indian company offers cheap anti-AIDS drugs. | 2001-02-15 |
|
| Galactorrhoea, hyperprolactinaemia, and protease inhibitors. | 2001-02-10 |
|
| South Africa's AIDS activists say new neviripine programme is not enough. | 2001-02-10 |
|
| South Africa cuts agreement for one AIDS drug but ignores another. | 2001-02 |
|
| Revised nevirapine insert. | 2001-02 |
|
| Further views by the Erice working group on mother-to-child transmission of HIV type 1. | 2001-01 |
|
| Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. | 2001-01 |
|
| A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. | 2001 |
|
| The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. | 2001 |
Sample Use Guides
The recommended dose for Nevirapine is one 200 mg tablet daily for the first 14 days, followed by one 200 mg tablet twice daily, in combination with other antiretroviral agents.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:17:55 GMT 2025
by
admin
on
Mon Mar 31 20:17:55 GMT 2025
|
| Record UNII |
B7XF2TD73C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1460714
Created by
admin on Mon Mar 31 20:17:55 GMT 2025 , Edited by admin on Mon Mar 31 20:17:55 GMT 2025
|
PRIMARY | |||
|
DBSALT002723
Created by
admin on Mon Mar 31 20:17:55 GMT 2025 , Edited by admin on Mon Mar 31 20:17:55 GMT 2025
|
PRIMARY | |||
|
100000127941
Created by
admin on Mon Mar 31 20:17:55 GMT 2025 , Edited by admin on Mon Mar 31 20:17:55 GMT 2025
|
PRIMARY | |||
|
NEVIRAPINE HEMIHYDRATE
Created by
admin on Mon Mar 31 20:17:55 GMT 2025 , Edited by admin on Mon Mar 31 20:17:55 GMT 2025
|
PRIMARY | Description: A white to almost white powder. Solubility: Practically insoluble in water, sparingly to slightly soluble in dichloromethane R, slightly soluble in methanol R. Category: Antiretroviral (Non-Nucleoside Reverse Transcriptase Inhibitor). Storage: Nevirapine should be kept in a well-closed container. Labelling: The designation on the container should state whether the substance is the hemihydrate or is in the anhydrous form. Definition: Nevirapine contains not less than 98.0% and not more than 102.0% of nevirapine (C15H14N4O), calculated with reference to the anhydrous substance. | ||
|
9959243
Created by
admin on Mon Mar 31 20:17:55 GMT 2025 , Edited by admin on Mon Mar 31 20:17:55 GMT 2025
|
PRIMARY | |||
|
2462459
Created by
admin on Mon Mar 31 20:17:55 GMT 2025 , Edited by admin on Mon Mar 31 20:17:55 GMT 2025
|
PRIMARY | |||
|
DTXSID30176606
Created by
admin on Mon Mar 31 20:17:55 GMT 2025 , Edited by admin on Mon Mar 31 20:17:55 GMT 2025
|
PRIMARY | |||
|
B7XF2TD73C
Created by
admin on Mon Mar 31 20:17:55 GMT 2025 , Edited by admin on Mon Mar 31 20:17:55 GMT 2025
|
PRIMARY | |||
|
B7XF2TD73C
Created by
admin on Mon Mar 31 20:17:55 GMT 2025 , Edited by admin on Mon Mar 31 20:17:55 GMT 2025
|
PRIMARY | |||
|
SUB34149
Created by
admin on Mon Mar 31 20:17:55 GMT 2025 , Edited by admin on Mon Mar 31 20:17:55 GMT 2025
|
PRIMARY | |||
|
220988-26-1
Created by
admin on Mon Mar 31 20:17:55 GMT 2025 , Edited by admin on Mon Mar 31 20:17:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
ANHYDROUS->SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
Amount Not Specified
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
The test is not valid unless the resolution between nevirapine and nevirapine impurity B RS is not less than 5. In the chromatogram obtained with solution (3) the peak due to impurity (B) is eluted at a relative retention of about 0.7 with reference to nevirapine (retention time about 7.6 minutes).
|
||
|
IMPURITY -> PARENT |
Amount Not Specified
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |